Fig. 5.

TAL1 was upregulated in glioma tissues and cells and exerted oncogenic function in glioma cells. a TAL1 mRNA expression levels in NBTs and glioma tissues. Data are presented as the mean ± SD (n = 7 in each group). **P < 0.01 versus NBTs group; ^##P < 0.01 versus Grade I group; ^△△P < 0.01 versus Grade II group; ^ΨΨP < 0.01 versus Grade III group. b TAL1 protein expression levels in NBTs and glioma tissues. **P < 0.01 versus NBTs group; ^##P < 0.01 versus low-grade glioma tissues group. c, d The expression levels of TAL1 mRNA and protein in NHA, U87 and U251 cells. Data are presented as the mean ± SD (n = 3 in each group); *P < 0.05, **P < 0.01 versus NHA group. e CCK-8 assay was used to explore the effect of TAL1 on proliferation in U87 and U251 cells. f Flow cytometry analysis of U87 and U251 with different expression of TAL1. g Transwell assays were used to measure the effect of TAL1 on cell migration and invasion of U87 and U251 cells. *P < 0.05, **P < 0.01 versus TAL1-NC group; ^#P < 0.05, ^##P < 0.01 versus sh-NC group. Scale bars represent 40 μm. h, k Western blot assay were used to detect the TAL1 expression after miR-346 (miR-425-5p) over-expression or knockdown. **P < 0.01 versus pre-NC group; ^##p < 0.01 versus anti-NC group. i, l Western blot assay were used to detect the TAL1 expression regulated by MIR17HG and miR-346 (miR-425-5p). **P < 0.01 versus sh-NC + pre-NC group. j, m The predicted miR-346 (miR-425-5p) binding sites in the 3’UTR region of TAL1 (TAL1–3’UTR-Wt) and the designed mutant sequence (TAL1–3’UTR-Mut) are indicated. Relative luciferase activity was conducted after cells were transfected with TAL1–3’UTR-Wt or TAL1–3’UTR-Mut. Data are presented as the mean ± SD (n = 3 in each group). **P < 0.01 versus TAL1-Wt + pre-NC group. Using one-way analysis of variance for statistical analysis